Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Ms. Karin L. Walker CPA

Chief Accounting Officer & Controller

Mr. Mark C. Johnson C.F.A.

Vice President of Investor Relations

Mr. David A. Ford

Chief People Officer

Mr. Michael J. Malecek

Chief Legal Officer

Dr. Wagner M. Zago

Chief Scientific Officer

Mr. Tran B. Nguyen M.B.A.

Chief Financial Officer & Chief Strategy Officer

Dr. Hideki  Garren M.D., Ph.D.

Chief Medical Officer

Dr. Gene G. Kinney Ph.D.

President, Chief Executive Officer & Director

Mr. Brandon S. Smith

Chief Operating Officer

Ms. Carol D. Karp

Chief Regulatory Officer

Bioteknik

Prothena Corporation plc

Prothena Corporation plc Ledningsstruktur

Information om ledningen